title: [Pharmacokinetics of bisphosphonate.]
abstract: The objective of treating osteoporosis is to prevent fractures. Bisphosphonates inhibit bone resorption and increase bone density, thereby suppressing the occurrence of fractures. Bisphosphonates have a high affinity for hydroxyapatite. About 20-80%of bisphosphonates absorbed in vivo is adsorbed onto the bone surface. However, the absorption rates of orally ingested bisphosphonates are less than 1%. Bisphosphonates adhered to the bone surface are specifically incorporated into cells upon bone resorption by osteoclasts. Thus, the cytoskeleton of osteoclasts is destroyed, and apoptosis is induced to suppress bone resorption. This article overviews the mechanisms of action and pharmacokinetics of bisphosphonates.
authors: Department of Biochemistry, Institute for Oral Science, Matsumoto Dental University, Japan.
authors: Midori
authors: M
authors: Nakamura
authors: Institute for Oral Science, Matsumoto Dental University, Japan.
authors: Masanori
authors: M
authors: Koide
authors: Department of Biochemistry, Institute for Oral Science, Matsumoto Dental University, Japan.
authors: Nobuyuki
authors: N
authors: Udagawa
mesh_terms: D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D004164:Diphosphonates / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D010010:Osteoclasts / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy
chemical_list: D004164:Diphosphonates